Showing results (11-20 of 26) with videos related to
Sort By:
Pageof 3
Clinical Pharmacology in Drug Development|January 10, 2019
An Open-Label, Randomized, Pivotal Bioequivalence Study of Oral RolapitantZhi-Yi Zhang, Jing Wang, Sujata Arora, et al.Antiviral Research|June 22, 2002
Adenovirus inhibition by peptidomimetic integrin antagonistsPaul J Hippenmeyer, Peter G Ruminski, Joseph G Rico, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 20, 2002
HIV risk behaviors among African American men in Los Angeles County who self-identify as heterosexualAmy Rock Wohl, Denise F Johnson, Sharon Lu, et al.AIDS Patient Care and Stds|July 26, 2003
Risk of opportunistic infection in the HAART era among HIV-infected Latinos born in the United States compared to Latinos born in Mexico and Central AmericaAmy Rock Wohl, Sharon Lu, Jane Turner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 gangliosidePaul B Chapman, Dianna Wu, Govind Ragupathi, et al.Advances in Radiation Oncology|July 26, 2017
Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancerVictor E Chen, Erin F Gillespie, Kaveh Zakeri, et al.Journal of Clinical Pharmacology|September 15, 2017
Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy VolunteersXiaodong Wang, Zhi-Yi Zhang, Sujata Arora, et al.Journal of Clinical Pharmacology|September 15, 2017
Bioequivalence of Intravenous and Oral Rolapitant: Results From a Randomized, Open-Label Pivotal StudyXiaodong Wang, Zhi-Yi Zhang, Daniel Powers, et al.Frontiers in Psychology|August 23, 2021
A Qualitative Approach to Understanding the Holistic Experience of Psychotherapy Among ClientsLee Seng Esmond Seow, Rajeswari Sambasivam, Sherilyn Chang, et al.Cancer Chemotherapy and Pharmacology|November 9, 2021
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trialAmita Patnaik, Glen J Weiss, Drew W Rasco, et al.Pageof 3